<DOC>
	<DOCNO>NCT02184091</DOCNO>
	<brief_summary>Study assess effect vary degree renal dysfunction hepatic insufficiency single-dose pharmacokinetics nevirapine nevirapine metabolite order establish appropriate dose and/or dose frequency renally- hepatically-impaired patient</brief_summary>
	<brief_title>Study Evaluate Effects Underlying Renal Hepatic Dysfunction Pharmacokinetics Nevirapine</brief_title>
	<detailed_description />
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Hepatic Insufficiency</mesh_term>
	<mesh_term>Nevirapine</mesh_term>
	<criteria>Male female patient race age 18 75 year weight within 30 % normal gender , height frame specify Metropolitan Life Insurance Table For patient renal group : stable creatinine clearance base two estimation take least 3 day apart , correspond one four group : Group 1 ( mild dysfunction ) = 50 ml/min &lt; = Creatinine Clearance ( CLcr ) &lt; 80 ml/min Group 2 ( moderate dysfunction ) = 30 ml/min &lt; = CLcr &lt; 50 ml/min Group 3 ( severe dysfunction ) = CLcr &lt; 30 ml/min Group 4 = endstage renal disease ( ESRD ) require dialysis For patient hepatic group Two baseline creatinine clearance ( take least 3 day apart ) &gt; 80 ml/min clinically diagnose hepatic insufficiency Class A B liver disease accord ChildPugh 's Classification ; subject must ChildPugh score 59 point For patient normal group , i.e . normal respect hepatic renal function match hepatic group regard gender , age ( + 10 year ) , weight ( + 30 pound ) smoke history Two baseline creatinine clearance ( take least 3 day apart ) &gt; 80 ml/min No abnormalities clinical laboratory evaluation Female patient childbearing potential must willing use reliable form contraception must include medically approved form barrier contraception Patients able provide write consent comply study requirement Female patient pregnant breastfeeding Seated systolic blood pressure either &lt; 100 mmHg &gt; 150 mmHg and/or heart rate either &lt; 50 beats/min &gt; 90 beats/min History illness drug allergy opinion investigator might confound result study pose additional risk administer nevirapine subject Patients acute illness hospitalization routine dialysis within 2 week prior study initiation Patients currently take overthecounter drug within 3 day prior study initiation , currently take prescription drug opinion investigator consultation Boehringer Ingelheim Pharmaceuticals Incorporated ( BIPI ) medical monitor pharmacokineticist might interfere absorption , distribution metabolism test drug Significant electrocardiogram ( ECG ) abnormality</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>